Pomerantz Law Firm Investigates Potential Securities Fraud at Sanara MedTech

Overview

Pomerantz Law Firm, a renowned legal entity specializing in securities and antitrust litigation, is currently investigating potential securities fraud claims involving Sanara MedTech, Inc. (NASDAQ: SMTI). This investigation has been initiated to safeguard the interests of the investors who may have suffered losses due to the company's operations.

Recent Developments

On November 11, 2025, Sanara MedTech made a shocking announcement regarding the discontinuation of its Tissue Health Plus (THP) program. The company's management stated that this decision was made to reallocate resources towards its primary surgical business, aiming for improved operational efficiency. However, the following day, Sanara reported substantial financial results that revealed a significant net loss from discontinued operations amounting to $31.2 million. This loss was prominently influenced by a non-cash asset impairment charge of $26.5 million, which was directly linked to the termination of the THP program.

These disclosures negatively impacted Sanara's stock, leading to a dramatic decline of $6.93 per share, or 24.7%, resulting in a closing price of $21.11 on November 12, 2025.

Legal Implications

The investigation spearheaded by Pomerantz LLP aims to uncover whether Sanara and its executives have engaged in any form of securities fraud or unlawful business practices that could potentially harm investors. This inquiry is particularly crucial given the mire of complexities associated with corporate securities. Pomerantz, which has established itself as a leading firm in this arena over the last 85 years, continues to advocate for the rights of investors amid corporate misconduct.

Contact Information

Investors who believe they may be affected by this situation are encouraged to reach out directly to attorney Danielle Peyton at Pomerantz LLP. Contact details include [email protected] and 646-581-9980, ext. 7980. Those interested in joining a class action are also prompted to make contact, pursuing justice for their potential losses.

Pomerantz's Legacy

Founded by Abraham L. Pomerantz, a notable pioneer in the field of class action lawsuits, Pomerantz LLP has been at the forefront of legal battles for investor rights. With a legacy that includes multi-million dollar recoveries for clients, the firm applies its extensive experience to navigate complex securities cases, demonstrating an unwavering commitment to upholding the rights of investors.

As this investigation unfolds, stakeholders within the financial community will be keenly observing how Sanara MedTech responds, both to the scrutiny from Pomerantz and to the broader implications of its recent operational changes. The outcome could shape the company's future and affect broader investor sentiments in the health tech sector.

For more robust updates on this situation and Pomerantz's ongoing work in defense of investor rights, you can follow developments on their official website at www.pomlaw.com.